Kennedy Capital Management’s Abeona Therapeutics ABEO Stock Holding History
Bought
Maintained
Sold
Other funds holding ABEO
ACM
AIC
Kennedy Capital Management's ABEO Position: Q3 2026 in Review
Kennedy Capital Management increased its Abeona Therapeutics (ABEO) stake by 7.3% in Q3 2026, buying an estimated $563K and bringing the position to 1,330,788 shares worth $6.99M. The position accounts for 0.13% of the portfolio, ranked #257.
Kennedy Capital Management first reported a position in ABEO in Q1 2025 and has held it in 7 quarters since. The position peaked at $7.66M in Q2 2026. 116 funds tracked by Wall St. Rank hold ABEO as of Q3 2026.
- Kennedy Capital Management held 1,330,788 shares of Abeona Therapeutics worth $6.99M as of Q3 2026.
- Kennedy Capital Management bought 90,717 Abeona Therapeutics shares in Q3 2026, an estimated $563K.
- Abeona Therapeutics made up 0.13% of Kennedy Capital Management's portfolio in Q3 2026, its #257 holding.
- Kennedy Capital Management first reported a position in Abeona Therapeutics in Q1 2025 and has held it in 7 quarters since.
- Kennedy Capital Management's Abeona Therapeutics position peaked at $7.66M in Q2 2026.
- 116 funds tracked by Wall St. Rank held Abeona Therapeutics as of Q3 2026.
Based on Kennedy Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.